On July 14, Tempus AI fell 5.05% in regular trading, trading at $55.24/share, with turnover of $175 million. The stock extended its decline as multiple negative factors continued to weigh on sentiment.

On the news front, Biovica International AB previously announced the termination of its collaboration agreement with Tempus AI, explicitly stating that the partnership failed to commercialize any product or generate any revenue. The termination reflects a setback in Tempus AI's ability to monetize certain partnerships. Additionally, CEO and Chairman Eric P. Lefkofsky sold approximately 126,250 shares of Class A common stock through a pre-arranged Rule 10b5-1 plan at prices ranging from $54.82 to $59.59 per share, adding to selling pressure. Freedom Capital Markets recently initiated coverage with a Hold rating and a $59 target price, which the stock has now fallen well below. The company is scheduled to report Q2 earnings on July 30, with consensus EPS expected at -$0.41.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)